Published in Cancer Weekly, September 28th, 2004
"Trastuzumab (herceptin) and pertuzumab (Omnitarg, 2C4) are recombinant humanized monoclonal antibodies that target different extracellular regions of the HER-2 tyrosine kinase receptor," oncologists in Texas explained.
R. Nahta and colleagues at the M.D. Anderson Cancer Center in Houston "explored combination effects of these agents in the HER-2-overexpressing BT474 breast cancer cell line."
"Trastuzumab and 2C4 synergistically inhibited the survival of BT474 cells, in part because of increased apoptosis," test results revealed. "Trastuzumab increased...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.